Key Insights Institutions' substantial holdings in Drugs Made In America Acquisition II implies that they have...
Drugs Made In America Acquisition II Corp. Unit (DMIIU) โ Live Session & Technical Brief
Updated Nov 22, 2026 6:33 AM ET ยท Prev Close $10.23
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (+0.29%) in Equities
Drugs Made In America Acquisition II Corp. Unit (DMIIU) is trading within a tight intraday band at $10.26 (+0.29%, 0.29x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, DMIIU is outperforming the S&P 500 by +3.93%. 14-day RSI stands at 48.4, keeping momentum in a bearish regime.
Key Insights Institutions' substantial holdings in Drugs Made In America Acquisition II implies that they have...
Price ($10.26) holds above both 20-day ($10.06) and 50-day ($10.05) moving averages.
Market & Sector Relative Strength
DMIIU outperforming the S&P 500 by +3.93%Recent DMIIU Catalyst Headlines
Verified WireFort Lauderdale, FL, Dec. 03, 2025 Globe Newswire -- Drugs Made In America Acquisition II Corp. the Company , a special purpose acquisition company formed as a Cayman Islands exempted company, today announced that commen
Fort Lauderdale, FL, Sept. 26, 2025 Globe Newswire -- Drugs Made In America Acquisition II Corp. Nasdaq DMIIU the Company today announced that it closed its initial public offering of 50,000,000 units at 10.00 per unit.
Fort Lauderdale, FL, Sept. 25, 2025 Globe Newswire -- Drugs Made In America Acquisition II Corp. Nasdaq DMIIU the Company announced today the pricing yesterday of its initial public offering of 50,000,000 units at 10.00
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $10.06 (20-day SMA support) for directional breakout confirmation.
Technical Regime (DMIIU)
MIXED MA TRENDRetail & Crowd Sentiment
NeutralAbout Drugs Made In America Acquisition II Corp. Unit
Drugs Made In America Acquisition II Corp is a blank check Company.
Get Instant DMIIU Catalyst Alerts
Receive an email alert when DMIIU triggers an unusual volume breakout, options sweep, or rating shift.
DMIIU Session & Catalyst FAQ
Why is DMIIU stock trading near flat today?
Drugs Made In America Acquisition II Corp. Unit (DMIIU) is trading within a tight intraday band at $10.26 (+0.29%, 0.29x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, DMIIU is outperforming the S&P 500 by +3.93%. 14-day RSI stands at 48.4, keeping momentum in a bearish regime.
Is DMIIU stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.29x relative volume (low participation). Our multi-factor model currently rates DMIIU as STRONG BUY. Review full valuation, quality, and timing signals on the DMIIU Buy or Sell Decision Brief โ
What is DMIIU's intrinsic value and expected trading range?
At $10.26, DMIIU's modeled 1-to-3 session range is $10.03 โ $10.49, with a key inflection level at $10.06 (20-day SMA support). Compare current price against multi-year cash flow projections in the DMIIU Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for DMIIU?
RSI at 48.4 reflects soft below-midline momentum. DMIIU trades at $10.26 relative to its 20-day SMA ($10.06) and 50-day SMA ($10.05), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.